Печеночная энцефалопатия: проблема фармакотерапии
https://doi.org/10.21518/2079-701X-2018-3-43-48
Аннотация
В статье представлены современные положения о патогенезе печеночной энцефалопатии, а также краткий обзор методов терапии. Приведен анализ доказательной базы эффективности препаратов L-орнитина-L-аспартата. Приводятся клинические наблюдения, свидетельствующие в пользу положительного влияния внутривенного применения препарата Орнилатекс у больных с клинически значимыми проявлениями печеночной энцефалопатии.
Об авторах
А. В. Полухина
Московский клинический научно-практический центр им. А.С. Логинова на базе Центрального научно-исследовательского института гастроэнтерологии
Россия
к.м.н.
Россия
к.м.н.
Т. Ю. Хайменова
Московский клинический научно-практический центр им. А.С. Логинова на базе Центрального научно-исследовательского института гастроэнтерологии
Россия
к.м.н.
Россия
к.м.н.
Е. В. Винницкая
Московский клинический научно-практический центр им. А.С. Логинова на базе Центрального научно-исследовательского института гастроэнтерологии
Россия
д.м.н.
Россия
д.м.н.
Список литературы
1. Rakoski MO, McCammon RJ, Piette JD, Iwashyna TJ, Marrero JA, Lok AS et al. Burden of cirrhosis on older Americans and their families: analysis of the health and retirement study. Hepatology, 2012, 55: 184-191.
2. Kaplan PW, Rossetti AO. EEG patterns and imaging correlations in encephalopathy: encephalopathy part II. J Clin Neurophysiol, 2011, 28: 233-251.
3. Papatheodoridis GV, Goulis J, Leandro G, Patch D, Burroughs AK. Transju-gular intrahepatic porto-systemic shunt compared with endoscopic treat ment for prevention of variceal rebleeding: a metaanalysis. Hepatology, 1999, 30: 612-622.
4. Nolte W, Wiltfang J, Schindler C, Munke H, Unterberg K, Zumhasch U et al. Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations. Hepatology, 1998, 28: 1215-1225.
5. Groeneweg M, Moerland W, Quero JC, Krabbe PF, Schalm SW. Screening of subclinical hepatic encephalopathy. J Hepatol, 2000, 32: 748-753.
6. Sharma P, Sharma BC, Puri V, Sarin SK. Critical flicker frequency: diagnostic tool for minimal hepatic encephalopathy. J Hepatol, 2007, 47: 67-73.
7. Bajaj JS. Management options for minimal hepatic encephalopathy. Expert Rev Gastroenterol Hepatol, 2008, 2: 785-790.
8. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissen born K, Blei AT. Hepatic encephalopathy: definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroentero logy, Vienna, 1998. Hepatology, 2002, 35: 716-721.
9. Cordoba J. New assessment of hepatic encephalopathy. J Hepatol, 2011, 54: 1030-1040.
10. Amodio P, Montagnese S, Gatta A, Morgan MY. Characteristics of minimal hepatic encephalopathy. Metab Brain Dis, 2004, 19: 253-267.
11. McCrea M, Cordoba J, Vessey G, Blei AT, Randolph C. Neuropsycho-logical characterization and detection of subclinical hepatic encephalopathy. Arch Neurol, 1996, 53: 758-763
12. Montagnese S, De Pitta C, De Rui M, Corrias M, Turco M, Merkel C et al. Sleep-wake abnormalities in patients with cirrhosis. Hepatology, 2014, 59: 705-712.
13. Delanty N, French JA, Labar DR Pedley TA, Rowan AJ. Status epilepticus arising de novo in hospitalized patients: an analysis of 41 patients. Seizure, 2001, 10: 116-119.
14. Prabhakar S, Bhatia R. Management of agitation and convulsions in hepatic encephalopathy. Indian J Gastroenterol, 2003, 22: S54-S58.
15. Weissenborn K, Bokemeyer M, Krause J, Ennen J, Ahl B. Neurological and neuropsychiatric syndromes associated with liver disease. AIDS, 2005, 19: S93-S98.
16. Victor M, Adams RD, Cole M. The acquired (non Wilsonian) type of chronic hepatocerebral degeneration. Medicine, 1965, 44: 345-396.
17. Bajaj JS, Schubert CM, Heuman DM, Wade JB, Gibson DP, Topaz A et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology, 2010, 138: 2332-2340.
18. Hepatic encephalopathy in chronic liver diseases: Clinical Practical Guide lines of the European Association for the Study of Liver Diseases and the American Association for the Study of Liver Diseases, 2014. J Hepatol, 2014. http: //dx.doi.org/10.1016/j.jhep.2014.05.042.
19. Montagnese S, Amodio P, Morgan MY. Methods for diagnosing hepatic encephalopathy in patients with cirrhosis: a multidimensional approach. Metab Brain Dis, 2004, 19: 281-312.
20. Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol, 2010, 7: 515-525.
21. Jones EA1. Pathogenesis of hepatic encephalopathy. Clin Liver Dis, 2000 May, 4(2): 467-85.
22. Pathogenesis of Hepatic Encephalopathy: Role of Ammonia and Systemic Inflammation. Journal of Clinical and Experimental Hepatology, 2015 Mar, 5(Suppl 1): S7.
23. Luo M, Guo JY, Cao WK. Inflammation: A novel target of current therapies for hepatic encephalopathy in liver cirrhosis. World J Gastroenterol, 2015 Nov 7, 21(41): 11815-24.
24. Patidar KR, Bajaj JS. Covert and overt hepatic encephalopathy: diagnosis and management. Clin Gastroenterol Hepatol, 2015 Nov, 13(12): 2048-61.
25. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med, 2010, 362: 1071-1081.
26. Gluud LL, Dam G, Borre M, Les I, Cordoba J, Marchesini G et al. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence? Metab Brain Dis, 2013, 28: 221-225.
27. Ventura-Cots M, Arranz JA, Simcin-Talero M, Torrens M, Blanco A, Riudor E et al. Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study. J Clin Gastroenterol, 2013, 47: 881-887.
28. Shawcross DL, Dunk AA, Jalan R, et al. How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist. Eur J Gastroenterol Hepatol, 2016 Feb. 28(2): 146-52.
29. Bai M1, Yang Z, Qi X, Fan D, Han G. l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of ran-domized controlled trials. J Gastroenterol Hepatol, 2013 May, 28(5): 783-92. doi: 10.1111/jgh.12142.
30. Stauch S, Kircheis G, Adler G, Beckh K, Ditschuneit H, Görtelmeyer R, Hendricks R, Heuser A, Karoff C, Malfertheiner P, Mayer D, Rösch W, Steffens J. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol, 1998 May, 28(5): 856-64.
31. Ndraha S, Hasan I, Simadibrata M. The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition. Acta Med Indones, 2011 Jan, 43(1): 18-22.
32. Schmid M, Peck-Radosavljevic M, König F, Mittermaier C, Gangl A, Ferenci P. A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis. Liver Int, 2010 Apr, 30(4): 574-82.
33. Pérez Hernández JL, Higuera de la Tijera F, Serralde-Zúñiga AE, Abdo Francis JM. Critical analysis of studies evaluating the efficacy of infusion of L-ornithine L-aspartate in clinical hepatic encephalopathy in patients with liver failure. Ann Hepatol. 2011 Jun, 10(Suppl 2): S66-9.
Рецензия
Для цитирования:
Полухина А.В., Хайменова Т.Ю., Винницкая Е.В. Печеночная энцефалопатия: проблема фармакотерапии. Медицинский Совет. 2018;(3):43-48. https://doi.org/10.21518/2079-701X-2018-3-43-48
For citation:
Polukhina A.V., Khaimenova T.Yu., Vinnitskaya E.V. Hepatic encephalopathy: features of pharmacotherapy. Meditsinskiy sovet = Medical Council. 2018;(3):43-48. (In Russ.) https://doi.org/10.21518/2079-701X-2018-3-43-48
Просмотров: 424
Послать статью по эл. почте 